Back to Search
Start Over
Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C.
- Source :
-
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2017 Sep; Vol. 49 (9), pp. 1029-1035. Date of Electronic Publication: 2017 Apr 27. - Publication Year :
- 2017
-
Abstract
- Background: The aim of this study was to clarify the effectiveness and safety of sofosbuvir/ribavirin therapy for elderly patients with genotype 2-infected chronic hepatitis C (CHC) in Japan.<br />Methods: A multicenter, retrospective study evaluated the effectiveness and safety of sofosbuvir/ribavirin based on real-world clinical data.<br />Results: The subjects consisted of 270 patients, 47.0% of whom were aged ≥65 years. The sustained virological response rates in patients aged <65 and ≥65 years were 98.6% and 95.3%, respectively. Hemoglobin levels decreased during treatment due to ribavirin-related hemolysis, and were significantly lower in patients aged ≥65 years than those aged <65 years at all time-points. A reduction in ribavirin dose was necessary in 31.0% (26/84) of patients with hemoglobin levels <13.0g/dL and in 70.7% (39/127) of those aged >65 years. Although the most frequent adverse event was anemia, no patients discontinued the use of either ribavirin or sofosbuvir. The incidence of ribavirin-related anemia in patients aged ≥65 years was 34.6% and significantly higher compared with that in patients aged <65 years (2.8%).<br />Conclusions: Treatment with sofosbuvir/ribavirin for genotype 2-infected CHC was effective and safe even for elderly patients, although the incidence of adverse events including ribavirin-related anemia was relatively high.<br /> (Copyright © 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Antiviral Agents adverse effects
Drug Therapy, Combination
Female
Hepacivirus
Hepatitis C, Chronic complications
Humans
Japan
Liver Cirrhosis drug therapy
Liver Cirrhosis virology
Logistic Models
Male
Middle Aged
RNA, Viral analysis
Retrospective Studies
Ribavirin adverse effects
Sofosbuvir adverse effects
Sustained Virologic Response
Antiviral Agents therapeutic use
Hepatitis C, Chronic drug therapy
Ribavirin therapeutic use
Sofosbuvir therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1878-3562
- Volume :
- 49
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
- Publication Type :
- Academic Journal
- Accession number :
- 28499694
- Full Text :
- https://doi.org/10.1016/j.dld.2017.04.012